Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00186 ...
Drug Name Lorazepam
Molecular Weight 321.158
Molecular Formula C15H10Cl2N2O2
CAS Number 846-49-1
SMILES OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
External Links
DRUGBANK DB00186
T3DB T3D4585
PubChem Compound 3958
PDR 2135
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Caco-2 Permeability 200.0 - 200.0 - Li C., Liu T., Ciu X., Uss A. and Cheng K. (2007). Society of Biomolecular Science.
Log P 2.39 - 2.39 - HANSCH,C ET AL. (1995)
Boiling Point 533.8 ℃ 533.8 ℃ Chemspider
Melting Point 193.0 ℃ 192-194 ℃ British Patent 1,022,642.
Water Solubility 80.0 mg/L 80 mg/L MERCK INDEX 1996)
pKa 13.0 - 13 - MERCK INDEX (1996); pK1
Log S -3.6 - -3.6 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % ~100 % IM,intramuscular injection; DRUGBANK
Bioavailability 90.0 % 90.0 % PO, oral; DRUGBANK
Bioavailability 93.0 % 93±10 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 48.0 ng/ml 48.0 ng/ml IM,intramuscular injection; DRUGBANK
C Max 28.0 ng/ml ~28 ng/ml PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 30.0 ng/ml ~30 ng/ml IM,intramuscular injection; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 75.0 ng/ml ~75 ng/ml intravenous injection, IV; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 2.0 h 2 h PO, oral; DRUGBANK
T Max 0.38 h 0.25-0.5 h IM,intramuscular injection; DRUGBANK
T Max 1.9 h 1.2-2.6 h PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.2 h 1.2 h IM,intramuscular injection; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 0.35 L/h/kg 5.8 ml/min/kg DRUGBANK
Clearance 0.0660 L/h/kg 1.1±0.4 ml/min/kg metabolism of ugt; Elderly → ;metastatic prostate cancer → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis ↑ ;Burn ↑ ;Somking → ; The Pharmacological Basis of Therapeutics
Clearance 0.0600 L/h/kg 1 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.3 L/kg 1.3 L/kg DRUGBANK
Volume of Distribution 1.3 L/kg 1.3±0.2 L/kg Apparent volume of distribution; Elderly → ;metastatic prostate cancer → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↑ ;Burn ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.3 L/kg 1.3 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 14.0 h 14 h parenteral administration; DRUGBANK
Half-life 14.0 h 14±5 h Neonates ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;CPBS → ;acute viral hepatitis AVH → ;Burn ↓ ;Age → ; The Pharmacological Basis of Therapeutics
Half-life 17.0 h 17 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 1850.0 mg/kg 1850.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 1850.0 mg/kg 1850.0 mg/kg PO, oral; mouse; T3DB
Toxicity LD50 3178.0 mg/kg 3178.0 mg/kg PO, oral; mouse; T3DB
Eliminate Route 88.0 % 88 % Urinary excretion; Oral single dose; normal,healthy; DRUGBANK
Eliminate Route 7.0 % 7 % Faeces excretion; Oral single dose; normal,healthy; DRUGBANK
Eliminate Route 0.30 % 0.3 % Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug; DRUGBANK
Eliminate Route 1.0 % <1 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 85.0 % 85 % DRUGBANK
Protein Binding 91.0 % 91±2 % Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Burn → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 10.0 mg/day 10 mg/day PO, oral Ativan Tablets lorazepam PDR
Max dose for children 4.0 mg/day 4 mg/day PO, oral Ativan Tablets lorazepam PDR
Max dose for adolescents 10.0 mg/day 10 mg/day PO, oral Ativan Tablets lorazepam PDR
Max dose for adolescents 4.0 mg/day 4 mg/day PO, oral Ativan Tablets lorazepam PDR
Max dose for adults 10.0 mg/day 10 mg/day PO, oral Ativan Tablets lorazepam PDR
Max dose for geriatric 10.0 mg/day 10 mg/day PO, oral Ativan Tablets lorazepam PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1